CheckMate 067: What the Melanoma Trial Found

The question CheckMate 067 asked

By 2013, two immunotherapy drugs worked in advanced melanoma. Nobody knew whether using them together beat using one.

Ipilimumab blocks a protein called CTLA-4. Nivolumab blocks a different one, PD-1. Both are checkpoint inhibitors. They take brakes off T cells so the immune system can attack cancer. Our overview of immunotherapy covers the class.

CheckMate 067 was built to answer that question in people who had not been treated yet.

How it was built

NCI's clinical summary describes the design. It was an international, double-blind trial in 945 people. All had stage III melanoma that could not be removed by surgery, or stage IV. None had been treated before.

They were split three ways in equal numbers:

• Nivolumab plus a placebo.
• Nivolumab plus ipilimumab, followed by nivolumab alone.
• Ipilimumab plus a placebo.

Progression-free survival and overall survival were both primary endpoints. One design detail matters here. The trial was powered to compare each nivolumab arm against ipilimumab alone. It was not powered to compare the combination against nivolumab by itself.

At the start, 31.5% of participants had a BRAF gene change and 36% had a raised LDH level. Fifty-eight percent had M1c disease, the most widespread category.

What the trial found

Progression-free survival was measured first, once everyone had at least nine months of follow-up. The median was 2.9 months on ipilimumab alone, 6.9 months on nivolumab alone, and 11.5 months on the combination.

The survival results came later. After at least five years of follow-up, median overall survival was 19.9 months in the ipilimumab group. It was 36.9 months in the nivolumab group. In the combination group it was more than 60 months, and had not been reached.

Five-year overall survival was 26% with ipilimumab, 44% with nivolumab, and 52% with the combination.

The report also found no lasting drop in quality of life during or after either nivolumab regimen. It found no new late toxic effects.

What "median not reached" means

"Not reached" is not a way of saying infinite. It means that when the researchers stopped counting, fewer than half the people in that group had died. So there was no midpoint to report yet.

It is an honest statement about the limits of the data. That is why the figure reads "more than 60 months" instead of a number.

What it cost

The combination was the most effective arm and by far the hardest.

NCI reports severe treatment-related side effects, graded 3 or 4, in 16.3% of the nivolumab group. The figure was 27.3% for ipilimumab and 55% for the combination.

The reason people stopped treatment differed by arm. In the two single-drug arms, most stopped because the cancer grew. That was 49% on nivolumab and 65% on ipilimumab. In the combination arm, the leading reason was toxicity, at 38%.

Four deaths in the trial were attributed to treatment. The causes were neutropenia, colon perforation, liver necrosis, and autoimmune myocarditis. That last one is immune-driven inflammation of the heart muscle.

When to get checked

Checkpoint inhibitors can make the immune system attack healthy organs. Those reactions are treatable when caught early. So anyone on this class of drug should report new symptoms right away, not at the next appointment. That includes diarrhea, a cough or breathlessness that will not settle, yellowing of the skin or eyes, chest pain with no clear cause, and unusual fatigue.

For melanoma itself, the reasons to book a skin check are specific. NCI says to see a doctor about a mole that changes in size, shape, or color. The same goes for one with ragged edges, more than one color, or halves that do not match. Add any spot that itches, oozes, bleeds, or has broken open. Add any new mole growing beside an older one. And show someone any spot wider than about 6 millimeters.

The wider picture

SEER is the federal cancer surveillance program. The 2026 forecast it carries — about 112,000 new melanoma diagnoses and 8,510 deaths in the United States — comes from the American Cancer Society. Five-year relative survival across all stages was 94.7% for people diagnosed from 2016 through 2022.

But only 5% of melanoma is found after it has spread to distant organs. Five-year relative survival in that group, over those same 2016–2022 diagnoses, is 34.0%. That small group is the one CheckMate 067 enrolled, and it is the group the trial's numbers describe. Our page on metastatic cancer covers what distant spread means.

What this trial cannot tell you

The trial was not built to prove the combination beats nivolumab alone. It compared each against ipilimumab. Any direct comparison between the two nivolumab arms is descriptive, not a statistical finding.

It also cannot tell you which arm suits one person. A 55% rate of severe side effects is a real trade for a higher survival curve. That trade lands differently depending on age, other health conditions, and what someone wants.

Finally, the participants were a selected group. They had no prior treatment, good performance status, and disease that surgery could not remove. NCI's analysis also found that PD-L1 levels alone did not reliably predict survival. There is still no clean test for who benefits most.

Sources

• Larkin J et al., Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma, N Engl J Med 2019 (NCBI E-utilities record)
• NCI PDQ: Melanoma Treatment (Health Professional Version)
• NCI PDQ: Melanoma Treatment (Patient Version)
• ClinicalTrials.gov record for NCT01844505 (CheckMate 067)
• NCI SEER Cancer Stat Facts: Melanoma of the Skin

How this article was prepared

An AI-assisted editorial system helped prepare this page. No named medical reviewer has reviewed it unless one is listed.

See an error, old source, or unclear wording? Tell us.